EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 7
Issue: 7
281-289
Year: 2020

AN OVERVIEW OF EPIGENETICS IN CANCER

Himanshu Upadhyay*

Amity Medical School, Amity University Haryana, Gurugram (Manesar)-12241.

***Corresponding Author: Himanshu Upadhyay**
Amity Medical School, Amity University Haryana, Gurugram (Manesar)-12241.

Article Received on 12/05/2020 **Article Revised on 02/06/2020** **Article Accepted on 23/06/2020**

ABSTRACT
Epigenetic and genetic changes make contributions to melanoma initiation and development. Epigenetic mechanisms are major for typical development and preservation of tissue-targeted gene expression patterns in mammals. Epigenetic changes are reversible and incorporate key programs of epigenetics mechanism are DNA methylation, chromatin changes, nucleosome positioning, histone modification and variations in noncoding RNA profiles. Cancer has been seen as genetic disease recently in some aspects, and now we are able to say that malignancy is preceded with the aid of epigenetic abnormalities.Epigenetic switching in cancer with more stable DNA methylation results in permanent silencing of key regulatory genes that may contribute to cell proliferation and carcinogenesis.Epigenetic therapy is used to reverse the causal epigenetic aberrations that arise in cancer, leading to the restoration of a normal epigenome.This evaluation study summarizes the mighty gain knowledge of epigenetic mechanism in tumors and suggestions of viable epigenetics therapy.

KEYWORDS: Epigenetics, DNA methylation, Histone modification, MiRNA, Chromatin, Epigenetic therapy.

Abbreviation
CpG: Here, C stands for cytosine, G stands for guanine and p is the phosphodiester bond between the C and G.
CpG island: The regions in the DNA that contain many adjacent cytosine and guanine nucleotides.
DNMT: DNA methyltransferase
MASPIN: Mammaryserineproteaseinhibitor
5-aza-CR: Azacitidine
5-aza-CDR: Decitabine
HDAC: Histone deacetylases.
MBD: Methyl-binding domain protein.
MeCP2: Methyl-CpG-binding proteins.
MYC: Regulator gene that codes for a transcription factor.
miRNA: MicroRNA.
RT-PCR: Real time polymerase chain reaction.

INTRODUCTION
Epigenetic and genetic changes make contributions to melanoma initiation and development.[1] Epigenetic mechanisms are major for typical development and preservation of tissue-targeted gene expression patterns in mammals.[2] Disturbance of epigenetic techniques can result in altered genes participate in and malignant cell change. Global changes inside the epigenetic scene are a pointer of melanoma. Chromatin structure characterizes the state wherein genetic data as DNA is composed inside a cell. This association of the genome into an exact reduced structure enormously impacts the capacities of the gene to be silenced or activated.[3] The concept of Epigenetics, first offered by using C.H. Waddington in 1939 to name as "the causal interactions between genes and their products, which carry the phenotype into being". Epigenetics was later outlined as heritable changes in gene expressions that aren't due to any alteration within the DNA sequence.[2, 4]

Quite often, cancer has been seen as genetic disease, and now we are able to say that melanoma is preceded with the aid of epigenetic abnormalities.[1] Current analysis in the quickly increasing discipline of epigenetics have proven broad reprogramming of component of the epigenetic equipment in melanoma including methylation of DNA, histone modification, position of nucleosome and non-coding RNAs, expression of primarily microRNA.[2, 5, 6]

The excellent-recognized epigenetic marker is DNA methylation.[6] Epigenetic study uses strongapproaches for the study of DNA methylation, reminiscent of sodium bisulfite change associated with PCR method.[7] However now a days, we participate in RT-PCR instead of PCR. Sodium bisulfite sequencing is used for therapy of DNA to determine its pattern of methylation.[2, 7]

Epigenetics refers back to the be trained of heritable changes in gene expression without changes in DNA sequences.[8] Epigenetic changes are reversible and

incorporate key programs of DNA methylation, chromatin changes, nucleosome positioning, and variations in noncoding RNA profiles.[2, 5, 6, 9] Disruptions in epigenetic techniques can outcomes in altered gene operate and cellular neoplastic transformation.[1] Epigenetic changes precede genetic changes and on the whole come up at an early stage in neoplastic progress.[8, 10]

Recent technological advances offer a greater working out of the undermodificative adjustment for the period of carcinogenesis and furnish insight into the invention of selective epigenetic biomarkers for detection, prognosis, comparison of risk factors, and monitoring disorders.[1] In this paper we provide understanding on quite a lot of overview of epigenetics and epigenetic switching, epigenetic changes in cancer cells and the abilities of epigenetic therapy.

Epigenetic changes in cancer cells

Cancer is a genetic disease initiated by alterations in genes, for example, oncogenes and tumor suppressors, that control cell multiplication, endurance, and other homeostatic capacities. In malignancy cells, genes are either changed by transformations, which modify the capacity of the proteins they encode or through epigenetics - modifications to chromosomes that alter gene-expression patterns.[11] Epigenetic changes in normal cell into the tumor cell as shown in figure1 how normal cell get methylated.



Figure 1: Source: Washington, DC: American Psychological Association. Retrieved October 27, 2011.

This can happen through DNA methylation, acetylation, or phosphorylation of histones and different proteins around which DNA is twisted to frame chromatin. Little is thought about how these chemical modifications happen in the DNA of malignant growth cells, yet they can influence expression patterns of oncogenes or of tumor suppressor genes. For instance, DNA methylation initiates "epigenetic suppressor" or the loss of articulation of tumor suppressor genes, causing normal cells to be changed into malignant growth cells.[4]

DNA methylation has critical roles in the control of gene activity and the structure of nucleus of the cell. In the human beings, DNA methylation occurs in the Cytosine that further changes to the Guanines; these are called dinucleotide CpGs. These CpG sites are not randomly distributed in the genome; in place of those sites usually CpG regions are rich so we called it CpG islands. These islands arise in roughly 40% of the promoters of human genes. These islands are most likely now not methylated in typical cells. Within the designated subgroups of CpG islands , methylation will also be detected inside the average tissues.[2, 3]

DNA Methylation

DNA methylation is might be essentially the most commonly studied epigenetic modification in mammals. Most original bio marker of epigenetics in cancer. It presents a stable gene suppressor mechanism that performs a major position in regulating gene expression and chromatin structure, in group with histone adjustments and other chromatin related proteins.In mammals, DNA methylation certainly happens by the covalent amendment of cytosine residues in CpG dinucleotides.[3]

CpG dinucleotides are not evenly allotted for the period of the human genome nevertheless are rather targeted in brief CpG-rich DNA stretches referred to as CpG islands and regions of massive repetitive sequences (e.g. Centromeric repeats, retrotransposon causes, rDNA and plenty of others.). CpG islands are preferentially placed at the 5'end of genes and occupy approximately 60% of human gene promoters. Whilst many of the CpG web sites in the genome are methylated, the majority of CpG islands in most cases remain unmethylated for the period of progress and in differentiated tissues.[7] However, some CpG island promoters come to be methylated for the duration of progress, which results in long-time period transcriptional suppressor. X-chromosome inactivation and imprinted genes are common examples of such naturally taking place CpG island methylation for the duration of development.[2]

Some tissue-particular CpG island methylation has additionally been suggested to occur in a type of somatic tissues, in particular at developmentally essential genes.[12] In distinction, the repetitive genomic sequences

which are scattered in every single place the human genome are closely methylated, which prevents chromosomal instability with the aid of suppressor non-coding DNA and transposable DNA elements. DNA methylation can outcomes in gene suppressor by means of utilizing either stopping or selling the recruitment of regulatory proteins to DNA.[6] For illustration, it could inhibit transcriptional activation by means of making use of blockading transcription explanations from gaining access to goal-binding internet sites e.g. C-MYC and MLTF. Then again, it might furnish binding websites for methyl-binding subject proteins, which is ready to mediate gene repression by way of interactions with histone deacetylases (HDACs). Thus, DNA methylation makes use of a form of mechanisms to heritably silence genes and non-coding genomic regions.[12]



Figure 2: An idea about the role of DNA methylation in cancer.

Source[13]

The unique DNA methylation patterns observed in the mammalian genome are generated and heritably maintained by the cooperative endeavor of the de novo methyltransferasesDNMT3A and DNMT3B, which act unbiased of replication and show equal choice for both unmethylated and hemi-methylated DNA and the preservation DNA methyltransferaseDNMT1, which acts for the duration of replication preferentially methylation hemi-methylated DNA. While the role of CpG island promoter methylation in gene suppressor is good headquartered, much less is known about the position of methylation of non-CpG island promoters. Latest reviews have shown that DNA methylation is also fundamental for the regular modification CpG island promoters.[14]

For illustration, tissue-specific expression of MASPIN, which does now not incorporate a CpG island inside its promoter, is regulated by using DNA methylation. In an identical approach, methylation of the non-CpG island Oct-4 promoter, strongly influences its expression level. Considering that CpG islands occupy simplest 60% of human gene promoters, it can be major to give an explanation for the position of non-CpG island methylation to be competent to absolutely realise the global position of DNA methylation in ordinary tissue.[3]

Table 1: DNA methylation genes altered in various human cancers.

DNA methylation genes altered in various human cancers		
Gene	**Cancer Type**	**Alteration**
DNA methyltransferase		
DNMT 1	colorectal, and ovarian cancer	upregulation and mutation
DNMT3b	colorectal, colon, breast, ovarian, oesophageal cancers, squamous cell carcinoma or multiple	Upregulation
Methyl-CpG-binding proteins		
MeCP2	prostate cancer, Rett syndrome	upregulation, mutation
MBD1	prostate, colon, and lung cancers	upregulation, mutation
MBD2	prostate, colon, lung cancers	upregulation, mutation
MBD3	colon, and lung cancer	upregulation, mutation
MBD4	colon, stomach, endometrium cancers	Mutation
Kaiso	colon, Intestinal, lung cancers	Upregulation

There are some other bio markers which also play big role in the epigenetics like miRNA, histone modification, nucleosome positioning**.**

MicroRNA

MicroRNA also called as Non-coding RNAs or non-profit coding. These are initially recognized for synergistic contributions to the development of RNA adhesion, although they later discover that they favor the epigenetic role of transcriptional quality transcriptionwhich might be expressed in a tissue-distinct method and manipulate a vast array of organic processes including cell proliferation, apoptosis and differentiation.[15,16] MiRNAs are 21-23 nucleotides long. Approximately 1,000 miRNA features in the human genome are statistically linked, with each miRNA focused on transcripts encoding multiple proteins. Although miRNAs are important in normal cell testing, their misexpression has been linked to cancer, and miRNA profiles are currently used to describe malignant human growth is represented in Table 2. Intracellular expression of miRNAs during cancer has been introduced.[17, 18] The impact of miRNA on epigenetic hardware and the concomitant direction of miRNA expression during cancer screening indicates a major change in the direction of epigenetics and malignant growth. Access direct and fluorescent sensing research for the link between miRNA and malignant growth.[18, 19] MiRNAs furnish opportunities for the progress of progressive biomarkers to help in disease detection, prognosis, analysis, prediction of response to healing.[20]

Table 3: MicroRNA alteration in various human cancers.

MicroRNA alteration in various human cancers			
MicroRNAs	**Target Genes**	**Cancer Type**	**Alterations**
miR-127	Bcl-6	bladder cancer	upregulation
miR-124	CDK6	colon cancer	upregulation
miR-223	NFI-A, MEF2C	acute myeloid leukemia	upregulation
miR-34b/34c	p53 network, CDK6, E2F3	colon cancer	upregulation
miR-17, miR-92	c-MYC	lung cancer	upregulation
miR-372,miR-373	RAS, p53 ,CD44	testicular germ cell tumor and breast cancer	upregulation
miR-21	PDCD4,PTEN,TPM1,RECK, TIMP3, BCL2	glioblastoma, breast, lung, prostate, colon and cervical cancer	Upregulation
miR-155	RHOA	Burkitt's lymphoma, breast ,colon, and lung cancers	Upregulation
miR-146	NF-κB	breast, pancreas and prostate cancers	Upregulation
miR-92b	PRMT5	brain primary tumors	Upregulation
miR-520	CD44	breast cancer	Upregulation

Covalent Histone modification

After methylation of the gene at the back of the structure, chromatin formation is affected by different histone changes and they play important roles in the regulation of quality and carcinogenesis.[21] Chromatin proteins complement as gaps in addition of eukaryotic DNA to elevated chromatin application cells.[2] Each nucleosome encodes ~146 bp of folded DNA over an octamer of histone proteins. These octamers form two components of the H2A, H2B, H3, and H4 Center protein complexes.[22] Histone proteins facilitate the progression between tightly packed DNA (heterochromatin) that is blocked to translate and reveal the DNA (euchromatin) available by the host and the translator's guidance material.[23] Histone proteins, which comprise the nucleosome core, include a globular C-terminal area and an unstructured N-terminal tail.The N-terminal tails of histones can endure a style of posttranslational covalent adjustments together with methylation, acetylation, ubiquitylation, sumoylation and phosphorylation on detailed residues.[5] These modifications regulate key cell approaches reminiscent of transcription, replication and repair. The complement of modifications is proposed to store the epigenetic reminiscence within a cell in the form of a histone code that determines the structure and exercise of specific chromatin areas.[9] Most of these changes occur in lysine, arginine, and serine deposits, and within the histone muscles of H3 and H4 proteins. This adjustment is reversed and controlled by the enzymes group. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are important insertion sites that can be reversed in these conformational changes. HDACs and HATs incorporate a large circle of ingredients that are displayed in several families and controls different physiological function of the cells.[24]

Moreover, to performing their individual roles, histone adjustments and DNA methylation interact with each and every different at a couple of stages to investigate gene expression status, chromatin organization and cellular identity.[9] The interactions between DNA methylation equipment and histone editing enzymes extra increase the complexity of epigenetic legislation of gene expression, which determines and maintains cell identity and performance.[3, 25]

Table 4: Histone modification genes altered in various human cancers.

Histone modification genes altered in various human cancers		
Histone Deacetylases	**Cancer type**	**Alteration**
HDAC1	colorectal cancer, cervical dysplasias, endometrial stromal sarcomas, gastric, prostate and colon cancer	upregulation/downregulation
HDAC2	multiple gastric carcinomas, colon cancer	upregulation/mutation
HDAC3	colon and prostate cancer	Upregulation
HDAC4	prostate, breast and colon cancers	upregulation/downregulation/mutation
HDAC5	colon cancer, AML	Repression
HDAC6	breast cancer, AML	Upregulation
HDAC7	colon cancer	Upregulation
HDAC8	colon cancer	Upregulation
SIRT1	colon cancer	upregulation/downregulation
SIRT2	Glioma	downregulation, deletion
SIRT3	breast cancer	upregulation
SIRT4	AML	downregulation

Nucleosome positioning

It plays an important role in how chromatin constitution regulates gene pastime. Additionally, to serve as the basic modules for DNA packaging within a cell, nucleosomes control gene expression by means of altering the accessibility of regulatory DNA sequences to transcription factors. The interaction of nucleosome reworking equipment with DNA methylation and histone modifications performs a pivotal function in commencing international gene expression patterns and chromatin structure.[3]

Epigenetic switching in cancer

For understanding the idea of epigenetic switching in cancer, we must clear our doubts that DNA methylation and histone modification is working independently but when we talk about the alteration in gene expression during carcinogenesis, it works together.[3] It is clear that such a nonspecific genetic change in neoplastic cells alone cannot explain multistep carcinogenesis in which tumor cells can communicate distinct phenotypes during critical periods of development and progression. Indeed, disease cells with a different altered epigenotype and tissue originate from them. Epigenetic changes are reflected in changes in the structure and organization of DNA methylation and histone remodelling, and this progression contributes to the phenotype of neoplastic cells.[26, 27] Most malignant growth cells protect the correct degrees of specificity of epigenetic catalysts; however, the effects of their response are not consistent with the phenotype, suggesting that there are several variants that influence their action.[28] For a very long time it has been observed that intestinal cells have a global hypomethylated genome, while at the same time central cytosine methylation has increased in particular regions of genome.[29] In normal cells, CpGs within the stranded DNA strands and character encoding regions are used as methylated, even though in plant cells LINE-1 is regenerated, satellite DNA, and modestly reprogramming DNA sequences, while containing the contents bunches of CpG become hypermethylated, giving a bit more transcriptionally silent them.[29, 30] Consistent changes in histone changes are evident in addition to injury. It has been shown that H3K4me3, H3K4me2, and H3ac are strongly enhanced by rotating the target initiation sites with downstream development of H3K4me1 and H4ac. In addition, the enhancement of H3K4me3, H3K4me2, and H3ac at the transcriptional level was seen as a strong association with the quality of action. Various circuits of histone modifications H3K4me1, 2, 3, and H3K36me3 correspond to quality input at full developmental levels at the first translation site, however H3K9me1, H3K20me1, and H3K27me1 correspond to quality specifications due to the high degrees of these downstream markers from the transcription start site and throughout the entire transcribed region.[30, 31] On the other hand, high levels of H3K27me2, 3, and H3K79me3 and modest H3K9me2 and 3 are linked to suppression of genetic quality and silencing. Fraga et al. first showed that the loss of H4K16ac and H4K20me3 is a common marker of human tumor cells associated with DNA hypermethylation at repeated sequences. Also, the deamination of methylated cytosine thymine structures, causing severe damage to deal with because DNA repair tools can only work with a great deal of discrimination.[32] At the translational level, a direct link between miRNAs and injury was demonstrated by the combination of Carlo Croce in 2002, indicating the loss of miR-15 and miR-16 in 13q14-induced chronic lymphocytic B-cell leukaemia.[17, 33] Epigenetic modifications to malignant growth can influence genome safety, providing a link between genome assembly and its replication and repair. This epigenetic switching in cancer with more stable DNA methylation results in permanent silencing of key regulatory genes that may contribute to cell proliferation and carcinogenesis.[3] A large part of the clarification work has shown the idea of such a change. However, there is some information is still unclear which transformation associate factor is switched. Furthermore, study is required for clarify the doubt.

Epigenetic therapy

As we know that epigenetics has the reversible nature by means of the help of epigenetic alterations that occur in cancer has preceded to the probability of epigenetic

cureas a therapy alternative.[2, 34] The goal of epigenetic therapy is used to reverse the causal epigenetic aberrations that arise in cancer,leading to the restoration of a 'normal epigenome.[35]

Up to now time, some of the epigenetic medicinal drugs are found out that can effective for reverse DNA methylation and histone change aberrations that arise in cancer. DNA methylation inhibitors have been among the many first epigenetic medications proposed for use as melanoma therapeutics.[36] The amazing discovery that therapy with cytotoxic retailers, 5-aza-CR and 5-aza-CDR, lead to the inhibition of DNA methylation that triggered gene expression and brought about differentiation in cultured cells led to the awareness of the expertise use of these medications in melanoma therapy.[37] These nucleoside analogues get incorporated into the DNA of quickly developing tumor cells during replication and inhibit DNA methylation by means of trapping DNA methyltransferases onto the DNA, leading to their depletion throughout the cell. This drug-prompted discount of DNA methylation explanations development inhibition in melanoma cells by activating tumor suppressor genes aberrantly silenced in melanoma. 5-Aza-CR and 5-aza-CdR have now been FDA accepted for use in to cure of myelodysplastic syndromes and promising results have additionally emerged from the therapy of other haematological malignancies similar to acute myeloid leukaemia and persistent myeloid leukaemia using thesemedicinal acetylation.[38, 39]

Aberrant gene suppressor in melanoma can also be related to a concomitant lack of histone acetylation. Re-establishing natural histone acetylation patterns through healing with HDAC inhibitors had been confirmed to have antitumorigenic results including growth arrest, apoptosis and the induction of differentiation.[4, 40] These antiproliferative results of HDAC inhibitors are mediated through their advantage to reactivate silenced tumor suppressor genes. Suberoylanilide hydroxamic acid (SAHA), which is an HDAC inhibitor, has now been authorized for use in health facility for treatment of T cell cutaneous lymphoma.[3]

Moreover, the synthetic miRNAs are tumor suppressor miRNAs. This can be utilized to selectively repress oncogenes in tumors. MiRNAs, reminiscent of miR-101. Truly miR-101 used for keep watch over the aberrant epigenetic mechanism in cancer that aid in restoring of the ordinary epigenome.[41]

In future potentialities, A combinatorial system using distinctive epigenetic therapeutic procedures along with traditional chemotherapy holds giant promise for successful medicine of melanoma in future. Such approaches might additionally help in sensitizing melanoma cells, exceptionally melanoma stem cells, which might be refractory to ordinary chemotherapy.

Review of literature

Esteller, M. (2008) found that Gene transcription may also be activated or inhibited by using a reversible change of the gene; this change is termed an epigenetic exchange. This account of epigenetics in melanoma reports the mechanisms and penalties of epigenetic changes in cancer cells and concludes with the implications of these changes for the diagnosis, prognosis, and healing of cancer.[2]

Sharma, Kelly et al. (2010) found that Epigenetic mechanisms are predominant for typical progress and renovation of tissue-special gene expression patterns in mammals. Disruption of epigenetic systems can result in altered gene perform and malignant cell transformation.World changes in the epigenetic area are a trademark of melanoma. The initiation and development of melanoma, undoubtedly apparent as a genetic sickness, is now realized to contain epigenetic abnormalities along with genetic alterations. Cutting-edge trends in the swiftly evolving area of cancer epigenetics have proven significant reprogramming of each aspect of the epigenetic machinery in melanoma in conjunction with DNA methylation, histone adjustments, nucleosome positioning and non-coding RNAs, above all microRNA expression. The reversible nature of epigenetic aberrations has ended in the emergence of the promising area of epigenetic therapy, which is already making growth with the present day FDA approval of three epigenetic medicinal drugs for cancer medicine.[3]

Sarkar, F. H. (Ed.). (2013) found that, Nutraceuticals, the bioactive food add-ons represented with the aid of many naturally happening dietary compounds, had been investigated for a couple of decades for his or her numerous beneficial results, together with their anticancer houses. The initial curiosity in the cancer-preventing/therapeutic ability of those agents used to be founded on their ability to have an impact on multiple signaling pathways which can be deregulated in cancer cells. With a shift in the focal point of melanoma be taught to the rising areas similar to epigenetic regulation.

Verma et.al. (2002) explained thecapabilities of the molecular events that occur during the early stages of cancer has evolved swiftly. The initiation and progress of cancer involves a couple of molecular alterations, which incorporate epigenetic transformations. Epigenetics is the be trained of changes in gene expression that don't contain alterations in DNA nucleotide sequences. Adjustments in gene expression via methylation of DNA and remodelling of chromatin by way of histone proteins are believed to be the predominant of the epigenetic changes.[42]

Peter A. Jones et al (1999) explained the invention of numerous hypermethylated promoters of tumour-suppressor genes, together with a reflector figuring out of gene-suppressor mechanisms, has moved DNA methylation from obscurity to recognition as a substitute

mechanism of tumour-suppressor inactivation in melanoma. Epigenetic pursuits can also facilitate genetic harm, as illustrated with the aid of the multiplied mutagenicity of 5-methylcytosine and the suppressor of the MLH1 mismatch repair gene through DNA methylation in colorectal tumours. We evaluate right here present mechanistic working out of the role of DNA methylation in malignant transformation, and advise two-hit speculation must now be improved to comprise epigenetic mechanisms of gene inactivation.[43]

Stephen B. Baylin et al (2002) explained the patterns of DNA methylation and chromatin constitution are profoundly altered in neoplasia and incorporate genome-broad losses of, and regional positive aspects in, DNA methylation. The recent explosion in our talents of how chromatin institution modulates gene transcription has extra highlighted the significance of epigenetic mechanisms within the initiation and development of human cancer. These epigenetic alterations in uncommon, aberrant promoter hypermethylation that is involving inappropriate gene suppressor influence almost each step-in tumour development. On this overview, we speak about these epigenetic events and the molecular alterations that could motive them and/or underlie altered gene expression in cancer.[12]

Martin Widschwendter et al (2007) explained theembryonic stem cells rely upon Polycomb staff proteins to reversibly repress genes required for differentiation. We file that stem cell Polycomb group ambitions are up to 12-fold more likely to have melanoma-specific promoter DNA hypermethylation than non-ambitions, helping a stem cell beginning of cancer wherein reversible gene repression is changed by everlasting suppressor, locking the cells into a perpetual state of self-renewal and thereby predisposing to subsequent malignant transformation.[44]

(Lund and van Lohuizen 2004) explained epigenetic tools work to alter access to your chromatin in transcriptional regulation and through modifications to DNA and to modifying or rearranging nucleosomes. The dominance of epigenetic quality interacts with genetic changes in the threat of developmental development. This is evident in all aspects of cytology, including cell proliferation and differentiation, cell cycle control, DNA repair, angiogeneis, transmission, and immunosuppression. In opposition to the causes of maternal threatening growth, the potential for epigenetic code may provide new insights into supportive interventions. They have deeply explained two events to demonstrate the importance of epigenetics in cancer formation. First, the influence of epigenetics on tumor growth is demonstrated by the importance of the extracellular matrix and tumor cell - cellular interactions. In addition to the importance of Mutation, immune mechanisms such as tumor cells escape the B53 and PRP pathways and the "telomere clock", the rate of successful development of harmful genes depending on their status. Thus, with the ability to stimulate or inhibit harmful growth, the microenvironment of the plant is recognized as an epigenetic module.Second, direct demonstration of the importance of epigenetics in the gastrointestinal processes is an effective treatment for cancer with inhibitors of epigenetic regators. Most of the discovered chemical agents indirectly block TNMT or HDICs, and some of these compounds are currently undergoing clinical trials. The importance of the epigenetic mechanisms of gene regulation in cancer is now recognized by cancer-related mechanisms that apply to all epilators. The study of epigenetic markings has taken place, as not all epigenetic markers are known, and only a small number of known people can see any details. Thus, the emergence of advanced tools such as methyl-specific histone antibodies and new chromatin research methods may provide immediate new insights into epigenetic regulation in normal growth and apoptosis.[23]

CONCLUSION

Understanding the complexity of the epigenome and all the factors involved in the modulating its interactions with genomic sequences is of fundamental importance in health and disease. By studying the DNA methylation of normal cell and tumour cell, we can say that epigenetic modification is reversible. Preserve promise for stopping and treating long-established human ailments including cancer. As, miRNAs provide opportunities for the progress of revolutionary biomarkers to help in disease detection, prognosis, diagnosis, prediction of response to treatment. Figuring out the complex mechanisms involved in epigenetics, may just result in extra potent for cancer healing and we can also inhibit DNA methylation which helps in promote to manipulate of malignant phenotypes.

REFERENCES

1. Kanwal R, Gupta S: Epigenetic modifications in cancer. *Clinical genetics*, 2012; 81(4): 303-311.
2. Esteller M: Epigenetics in cancer. *New England Journal of Medicine*, 2008; 358(11): 1148-1159.
3. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. *Carcinogenesis*, 2010; 31(1): 27-36.
4. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. *Nature*, 2004; 429(6990): 457-463.
5. Lennartsson A, Ekwall K: Histone modification patterns and epigenetic codes. *Biochimica et biophysica acta (BBA)-general subjects*, 2009; 1790(9): 863-868.
6. Kulis M, Esteller M: DNA methylation and cancer. In: *Advances in genetics.* vol. 70: Elsevier, 2010; 27-56.
7. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proceedings of the national academy of sciences*, 1996; 93(18): 9821-9826.
8. Erkovan A, Sirin H: Epigenetics and Cancer.

9. Li E: Chromatin modification and epigenetic reprogramming in mammalian development. *Nature Reviews Genetics*, 2002; 3(9): 662-673.
10. Wolffe AP: Introduction. In: *Novartis Foundation Symposium 214-Epigenetics: 1998*: Wiley Online Library, 1998; 1-5.
11. GRØNBÆK K, Hother C, Jones PA: Epigenetic changes in cancer. *Apmis*, 2007; 115(10): 1039-1059.
12. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. *Nature Reviews Genetics*, 2002; 3(6): 415-428.
13. Robertson KD: DNA methylation and human disease. *Nature Reviews Genetics*, 2005; 6: 597.
14. Rhee I, Bachman KE, Park BH, Jair K-W, Yen R-WC, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature*, 2002; 416(6880): 552.
15. Chuang JC, Jones PA: Epigenetics and microRNAs. *Pediatric research*, 2007; 61(7): 24-29.
16. Saetrom P, Snøve O, Rossi JJ: Epigenetics and microRNAs. *Pediatric research*, 2007; 61(7): 17-23.
17. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proceedings of the national academy of sciences*, 2004; 101(9): 2999-3004.
18. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs—the micro steering wheel of tumour metastases. *Nature Reviews Cancer*, 2009; 9(4): 293-302.
19. Rouhi A, Mager DL, Humphries RK, Kuchenbauer F: MiRNAs, epigenetics, and cancer. *Mammalian Genome*, 2008; 19(7-8): 517.
20. Ahmad A, Li Y, Bao B, Kong D, Sarkar FH: Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals. *Molecular nutrition & food research*, 2014; 58(1): 79-86.
21. Ellis L, Atadja PW, Johnstone RW: Epigenetics in cancer: targeting chromatin modifications. *Molecular cancer therapeutics*, 2009; 8(6): 1409-1420.
22. Zhang Y, Ng H-H, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. *Genes & development*, 1999; 13(15): 1924-1935.
23. Lund AH, van Lohuizen M: Epigenetics and cancer. *Genes & development*, 2004; 18(19): 2315-2335.
24. Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. *Nature Reviews Genetics*, 2009, 10(1): 32-42.
25. Cedar H, Bergman Y: Linking DNA methylation and histone modification: patterns and paradigms. *Nature Reviews Genetics*, 2009; 10(5): 295.
26. Clark SJ: Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. *Human Molecular Genetics*, 2007; 16(R1): R88-R95.
27. Ducasse M, Brown MA: Epigenetic aberrations and cancer. *Molecular cancer*, 2006; 5(1): 60.
28. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. *Nature Reviews Genetics*, 2006; 7(1): 21-33.
29. Reik W, Dean W, Walter J: Epigenetic reprogramming in mammalian development. *Science*, 2001; 293(5532): 1089-1093.
30. Kanwal R, Gupta S: Epigenetics and cancer. *Journal of applied physiology*, 2010; 109(2): 598-605.
31. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK: Global levels of histone modifications predict prognosis in different cancers. *The American journal of pathology*, 2009; 174(5): 1619-1628.
32. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. *Nature genetics*, 2005; 37(4): 391-400.
33. Villa R, De Santis F, Gutierrez A, Minucci S, Pelicci P, Di Croce L: Epigenetic gene silencing in acute promyelocytic leukemia. *Biochemical pharmacology*, 2004; 68(6): 1247-1254.
34. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. *Nature reviews Drug discovery*, 2006; 5(1): 37-50.
35. Jones PA, Baylin SB: The epigenomics of cancer. *Cell*, 2007; 128(4): 683-692.
36. Yang X, Lay F, Han H, Jones PA: Targeting DNA methylation for epigenetic therapy. *Trends in pharmacological sciences*, 2010; 31(11): 536-546.
37. Momparler RL: Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). In: *Seminars in oncology: 2005*: Elsevier, 2005; 443-451.
38. Yoo C, Cheng J, Jones P: Zebularine: a new drug for epigenetic therapy. In.: Portland Press Limited; 2004.
39. Brown R, Strathdee G: Epigenomics and epigenetic therapy of cancer. *Trends in molecular medicine*, 2002; 8(4): S43-S48.
40. Ganesan A, Nolan L, Crabb S, Packham G: Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. *Current cancer drug targets*, 2009; 9(8): 963-981.
41. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. *Biochemical and biophysical research communications*, 2009; 379(3): 726-731.
42. Verma M, Srivastava S: Epigenetics in cancer: implications for early detection and prevention. *The lancet oncology*, 2002; 3(12): 755-763.

43. Jones PA, Laird PW: Cancer-epigenetics comes of age. *Nature genetics*, 1999; 21(2): 163-167.
44. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I: Epigenetic stem cell signature in cancer. *Nature genetics*, 2007; 39(2): 157-158.